Table 1.
Timeframe of treatment and events
| Time | Event | Figure |
|---|---|---|
| November 2005 | CT scan of primary tumour and surgery | Fig. 1.1 |
| April 2006 | Recurrence on CT imaging in the lymph nodes in the lower pelvic and in inguinal | |
| April 2006 | First-line imatinib 400 mg × 1 orally daily | |
| May 2006 | Progression* on CT imaging | |
| July 2006 | Imatinib dose escalation to 400 mg × 2 orally daily | |
| July 2006 | Imatinib stopped due to allergic reaction | |
| August 2006 | Imaging with no signs of recurrent GIST. In conclusion, the presumed tumour recurrence on CT imaging was most likely a reactive change | |
| November 2007 | PET-CT shows 3 intra-abdominal tumours | Fig. 1.2 |
| November 2007 | Reintroduction of imatinib 200 mg × 1 orally daily. Stopped due to allergic reaction | |
| November 2007 | Second-line sunitinib 25 mg × 1 increased to 37.5 mg × 1 orally daily | |
| February 2008 | Progression* of disease | |
| February 2008 | Third-line nilotinib 400 mg × 2 orally daily | |
| March 2008 | Progression* of disease and no treatment options | |
| March 2008 | Reintroduction of imatinib 200 mg × 1 orally daily during prednisolone coverage. Stopped again due to allergic reaction | |
| April 2008 | Reintroduction of nilotinib 200 mg × 2 orally daily, increasing the dose gradually to nilotinib 400 mg × 2 orally daily | |
| June 2008 | Progression* of disease | |
| August 2008 | Baseline CT imaging before starting treatment with sorafenib | Fig. 1.3 |
| September 2008 | Fourth-line sorafenib 400 mg × 2 orally daily | |
| August 2009 | Partial regression* of the disease on CT scan | Fig. 1.4 |
| September 2009 | Complete resection of multiple GIST metastases intra-abdominally. Resumes sorafenib 200 mg × 2 orally daily postoperative | |
| September 2012 | Non-ST segment elevation myocardial infarct treated with a coronary artery bypass graft | |
| May 2013 | The dose of sorafenib was reduced further due to toxicity and was at this time 200 × 1 mg orally daily | |
| September 2015 | Non-ST segment elevation myocardial infarct treated with a percutaneous coronary intervention | |
| October 2016 | Diagnosed with proteinuria which was treatment related | |
| September 2017 | Progression* of disease. CT scan shows a tumour in relation to the terminal ileum | Fig. 1.5 |
| October 2017 | Increased dose of sorafenib to 400 mg orally once daily | |
| January 2018 | CT scan shows 15% reduction of tumour size | Fig. 1.6 |
| February 2018 | Macroradical surgery of GIST recurrence. Continued treatment with sorafenib 400 mg × 1 orally daily | |
| March 2021 | Still no signs of GIST recurrence | Fig. 1.7 |
GIST, gastrointestinal stromal tumour.
*
According to RECIST 1.1 [7].